AtriCure (NASDAQ:ATRC) Issues FY 2026 Earnings Guidance

Posted by Brenda Bartman on Jul 25th, 2026

AtriCure (NASDAQ:ATRC – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.240-0.320 for the period, compared to the consensus estimate of 0.120. The company issued revenue guidance of $602.0 million-$610.0 million, compared to the consensus revenue estimate of $605.0 million.

AtriCure Price Performance

ATRC opened at $35.04 on Friday. The stock’s 50-day moving average price is $30.05 and its 200 day moving average price is $31.42. AtriCure has a 12-month low of $25.36 and a 12-month high of $43.18. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of 166.87 and a beta of 1.24. The company has a current ratio of 4.29, a quick ratio of 3.18 and a debt-to-equity ratio of 0.15.

AtriCure (NASDAQ:ATRC – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.37%. During the same period in the prior year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts expect that AtriCure will post 0.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ATRC has been the topic of several recent research reports. Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a report on Tuesday. Weiss Ratings downgraded shares of AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. Canaccord Genuity Group lifted their price objective on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, Raymond James Financial set a $52.00 price target on AtriCure in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, AtriCure currently has an average rating of “Moderate Buy” and an average price target of $49.12.

Check Out Our Latest Stock Report on AtriCure

Insiders Place Their Bets

In other news, Director Karen Prange sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $28.65, for a total value of $85,950.00. Following the transaction, the director owned 26,373 shares of the company’s stock, valued at approximately $755,586.45. The trade was a 10.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.00% of the company’s stock.

AtriCure News Roundup

Here are the key news stories impacting AtriCure this week:

Positive Sentiment: Q2 earnings of $0.18 per share beat the $0.03 consensus and improved from a loss a year ago, showing a meaningful profitability turnaround. AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
Positive Sentiment: Revenue of $153.6 million topped Wall Street estimates of $151.8 million, reinforcing that demand remains solid. AtriCure Reports Second Quarter 2026 Financial Results
Positive Sentiment: The company lifted FY2026 EPS guidance to $0.24-$0.32, well above the prior consensus, and revenue guidance of $602 million-$610 million is also near or slightly above expectations. AtriCure Reports Second Quarter 2026 Financial Results
Positive Sentiment: Management described the quarter as one of “healthy growth” and a “significant step up in profitability,” which supports the recent stock strength. AtriCure Reports Second Quarter 2026 Financial Results
Neutral Sentiment: Short-interest data showed 0 reported shares, so it does not appear to be a meaningful trading catalyst.

Hedge Funds Weigh In On AtriCure

A number of large investors have recently bought and sold shares of the company. Captrust Financial Advisors boosted its stake in shares of AtriCure by 7.9% in the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock valued at $314,000 after buying an additional 579 shares in the last quarter. Arete Wealth Advisors LLC purchased a new stake in shares of AtriCure during the 4th quarter worth $222,000. Brooklyn Investment Group acquired a new position in shares of AtriCure during the 4th quarter worth $202,000. Quadrant Capital Group LLC acquired a new stake in shares of AtriCure in the third quarter valued at about $198,000. Finally, State of Tennessee Department of Treasury purchased a new stake in AtriCure during the second quarter worth about $184,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.